Rare Nrg1 Fusion Epidemiology Forecast

DelveInsight’s ‘Rare NRG1 Fusion - Epidemiology Forecast–2032’ report delivers an in-depth understanding of the disease, historical and forecasted epidemiology in the United States, EU-5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Rare NRG1 Fusion Understanding

NRG1 (Neuregulin 1) gene fusions are potentially actionable oncogenic drivers that are present in some solid tumors. NRG1 fusions result in ErbB-mediated pathway activation and present a rational therapeutic target. Oncogenic fusions of NRG1 may cause excess accumulation of the NRG1-fusion protein at the cell surface. This causes persistent activation of ErbB receptor tyrosine kinases that drive excess activity in the mTOR and MAPK pathways and promote tumorigenesis. The NRG1 gene encodes ligands for the ERBB2 (HER2)-ERBB3 heterodimeric receptor tyrosine kinase. Gene fusions of NRG1 such as CD74-NRG1 and SLC33A2-NRG1 have been found at low frequency in a wide range of carcinomas including lung, breast, colorectal, ovarian, and pancreatic cancers and with a wide range of fusion partners.

 

CD74-NRG1 fusion gene has been identified in a portion of invasive mucinous adenocarcinomas (IMA) of the lung. However, the function of the CD74-NRG1 fusion gene in adenocarcinoma pathogenesis and the mechanisms by which it may impart protumorigenic characteristics to cancer stem cells (CSC) is still unclear. A range of NRG1 fusion partners beyond CD74 has been identified, and they also vary among cancer types. In NSCLC, other fusion partners include the SDC4, SLC3A2, and ATP1B1 genes. In other malignancies, the genes SETD4, TSHZ2, and ZMYM2 (ovarian cancer); ADAM9 and COX10-AS1 genes (breast cancer); and CDH1 and VTCN1 genes (pancreatic cancer) are among known fusion partners of NRG1.

 

Rare NRG1 Fusion Diagnosis

Fusions involving the neuregulin-1 gene (NRG1) were first identified by transcriptome sequencing of lung adenocarcinomas, which revealed fusion of CD74 to NRG1. NRG1-fusion proteins and genes in solid tumors are detected primarily using immunohistochemistry and fluorescence in situ hybridization (FISH) techniques, DNA next-generation sequencing (NGS), and targeted gene fusion panels on RNA. The gold standard for the detection of NRG1 gene fusions is RNA sequencing in comparison with DNA sequencing. Although fluorescence in situ hybridization (FISH) can be used as a pre-screening method for its detection, only genetic sequencing will allow the identification of the gene fusion. RNA-sequencing is associated with higher sensitivity for genetic rearrangements and can increase the detection of NRG1 gene fusions compared with DNA-based methods, which often do not cover the large introns in NRG1.

Epidemiology Perspective by DelveInsight

The Rare NRG1 Fusion epidemiology division provides insights about the historical and current Rare NRG1 Fusion patient pool and forecasted trends for seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

In the year 2021, the total incident case of Rare NRG1 Fusion were 5,733 cases in the 7MM which are expected to grow during the study period, i.e., 2019–2032.

 

The disease epidemiology covered in the report provides historical as well as forecasted Rare NRG1 Fusion epidemiology [segmented as Total Incident Cases of NRG1 Fusion, Total Stage-specific Cases of NRG1 Fusion, and Total Treated cases of NRG1 Fusion] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

Country Wise- Rare NRG1 Fusion Epidemiology

  • Estimates show that the highest cases of NRG1 Fusion in the 7MM were in the United States, followed by Japan, Germany, France, Italy, the United Kingdom, and Spain in 2021.
  • The incident cases include the following cancers; cholangiocarcinoma, pancreatic cancer, renal cell carcinoma, ovarian cancer, NSCLC, breast cancer, bladder cancer, and colorectal cancer.
  • In the United States, the total number of incident cases of NRG1 Fusion were 2,122 cases in the year 2021 which are expected to grow during the study period, i.e., 2019–2032.
  • In the year 2021, the total incident cases of NRG1 Fusion in EU-5 were highest in Germany which are expected to grow during the study period, i.e., 2019–2032.
  • In Japan, the total number of incident cases of NRG1 Fusion was 1,201 cases in the year 2021 which are expected to grow during the study period, i.e., 2019–2032.
  • In the US, NSCLC and Breast cancer has the highest number of the NRG1 fusion cases.
  • In the US, the total NRG1 fusions metastatic cases (including locally advanced) was 1,076 in the year 2021 which are expected to grow during the study period, i.e., 2019–2032.

Scope of the Report

  • The Rare NRG1 Fusion report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
  • The Rare NRG1 Fusion Report and Model provide an overview of the risk factors and global trends of Rare NRG1 Fusion in the seven major markets (7MM: The United States, Germany, France, Italy, Spain, and the United Kingdom and Japan)
  • The report provides insight about the historical and forecasted patient pool of Rare NRG1 Fusion in seven major markets covering the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of Rare NRG1 Fusion.
  • The report provides the segmentation of the Rare NRG1 Fusion epidemiology by total incident cases in the 7MM.
  • The report provides the segmentation of the Rare NRG1 Fusion epidemiology by total stage-specific cases in the 7MM.
  • The report provides the segmentation of the Rare NRG1 Fusion epidemiology by total treated cases in the 7MM.

Report Highlights

  • 11-Year Forecast of Rare NRG1 Fusion epidemiology
  • 7MM Coverage
  • Total Incident Cases of Rare NRG1 Fusion
  • Total Stage-specific Cases of Rare NRG1 Fusion
  • Total Treated Cases of Rare NRG1 Fusion

KOL-Views

We interview KOL’s and SMEs ' opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM concerning the patient population of Rare NRG1 Fusion?
  • What are the key findings of the Rare NRG1 Fusion epidemiology across the 7MM and which country will have the highest number of patients during the study period (2019–2032)?
  • What would be the total number of patients of Rare NRG1 Fusion across the 7MM during the study period (2019–2032)?
  • Among the EU5 countries, which country will have the highest number of patients during the study period (2019–2032)?
  • At what CAGR the patient population is expected to grow in the 7MM during the study period (2019–2032)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of Rare NRG1 Fusion?

Reasons to buy

The Rare NRG1 Fusion Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Rare NRG1 Fusion market
  • Quantify patient populations in the global Rare NRG1 Fusion market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the gender that presents the best opportunities for Rare NRG1 Fusion therapeutics in each of the markets covered
  • Understand the magnitude of the Rare NRG1 Fusion population by its severity
  • The Rare NRG1 Fusion epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
  • The Rare NRG1 Fusion Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Executive Summary of Rare NRG1 Fusion

4. Epidemiology Methodology

5. Disease Background and Overview

5.1. Introduction

5.2. Cancers related to Solid tumor

5.2.1. Brain Tumor

5.2.2. Bladder Cancer

5.2.3. Breast Cancer

5.2.4. Lung Cancer

5.2.5. Colorectal cancer

5.2.6. Pancreatic ductal adenocarcinoma

5.2.7. Prostate cancer

5.2.8. Ovarian cancer

5.2.9. Kidney cancer

5.2.10. Common Pediatric Solid Tumor Cancers

5.3. Mutations in Cancers related to Solid Tumor

5.3.1. KRAS Mutation

5.3.2. ALK Mutation

5.3.3. PIK3CA Mutation

5.3.4. BRAF Mutation

5.3.5. MET Mutation

5.3.6. ROS1 mutation

5.3.7. HER2 Mutation

5.3.8. EGFR Mutation

5.3.9. NRG1 fusion

5.4. Normal function of Neuregulin

5.4.1. Oncogenic mechanism of NRG1 fusion

5.4.2. NRG1 Fusions by tumor type

5.4.3. Fusion partners of neuregulins

5.5. Diagnosis

5.5.1. Next-Generation Sequencing (NGS)

5.5.2. Immunohistochemistry (IHC)

5.5.3. Fluorescence in situ hybridization (FISH)

5.5.4. Targeted RNA-sequencing (RNA-Seq)

5.5.5. Anchored Multiplex PCR (AMP)

6. Biomarker Testing

6.1. Country-wise Scenario of Biomarker Testing

6.1.1. United States

6.1.2. Europe

6.1.3. Japan

6.2. Market Access and Reimbursement for Biomarker Testing

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. Assumptions and Rationale

7.3. Epidemiology Scenario: 7MM

7.3.1. Total Incident Cases of NRG1 Fusion

7.4. The United States

7.4.1. Total Incident Cases of NRG1 Fusion

7.4.2. Total Stage-specific Cases of NRG1 Fusion

7.4.3. Total Treated Cases of NRG1 Fusion

7.5. EU-5

7.5.1. Total Incident Cases of NRG1 Fusion

7.5.2. Total Stage-specific Cases of NRG1 Fusion in EU-5

7.5.3. Total Treated Cases of NRG1 Fusion

7.6. Japan

7.6.1. Total Incident Cases of NRG1 Fusion

7.6.2. Total Stage-specific Cases of NRG1 Fusion

7.6.3. Total Treated Cases of NRG1 Fusion

8. Unmet Needs

9. Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

List of Tables

Table 1: Summary of Rare NRG1 Fusion Market and Epidemiology (2019–2032)

Table 2: Genomic Testing Method

Table 3: The advantages and disadvantages of different assays available for the detection of NRG1

Table 4: ErbB-targeted treatment in patients with NRG1 fusion-positive tumors

Table 5: Total Incident Cases of NRG1 Fusion in the 7MM (2019–2032)

Table 6: Total Incident Cases of NRG1 Fusion in the United States (2019–2032)

Table 7: Total Stage-specific Cases of NRG1 Fusion in the United States (2019–2032)

Table 8: Total Treated Cases of NRG1 Fusion in the United States 2019–2032)

Table 9: Total Incident Population of NRG1 in the EU-5 (2019–2032)

Table 10: Total Stage-specific Cases of NRG1 Fusion in the EU-5 (2019–2032)

Table 11: Total Stage-specific Cases of NRG1 Fusion in Germany (2019–2032)

Table 12: Total Stage-specific Cases of NRG1 Fusion in France (2019–2032)

Table 13: Total Stage-specific Cases of NRG1 Fusion in Italy (2019–2032)

Table 14: Total Stage-specific Cases of NRG1 Fusion in Spain (2019–2032)

Table 15: Total Stage-specific Cases of NRG1 Fusion in the UK (2019–2032)

Table 16: Total Treated Population of NRG1 in the EU-5 (2019–2032)

Table 17: Total Incident Cases of NRG1 Fusion in Japan (2019–2032)

Table 18: Total Stage-specific Cases of NRG1 Fusion in Japan (2019–2032)

Table 19: Total Treated Cases of NRG1 Fusion in the Japan (2019–2032)

List of Figures

Figure 1: Various types of Solid tumors

Figure 2: Osteosarcoma

Figure 3: KRAS GTPase Cycle

Figure 4: ALK Gene Arrangements

Figure 5: PI3K Signaling Cascade

Figure 6: MAP Kinase Pathway

Figure 7: HGF/MET Pathway

Figure 8: Mechanism of action of NRG1

Figure 9: Oncogenic mechanisms of NRG1 fusions

Figure 10: NRG1 Fusion by Tumor type

Figure 11: NRG1 Fusion Partners

Figure 12: CD74-NRG1 Fusion pathway

Figure 13: CD74-NRG1 Fusion pathway

Figure 14: Novel treatment options for NRG1 Fusion

Figure 15: Global Heat Map of All Cancers

Figure 16: Total Incident Cases of NRG1 Fusion in the 7MM (2019–2032)

Figure 17: Total Incident Cases of NRG1 Fusion in the United States (2019–2032)

Figure 18: Total Stage-specific Metastatic (including locally advanced) Cases of NRG1 Fusion in the US (2019–2032)

Figure 19: Total Treated Cases of NRG1 Fusion in the United States (2019–2032)

Figure 20: Total Incident Cases of NRG1 Fusion in EU-5 (2019–2032)

Figure 21: Total Stage-specific Metastatic (including locally advanced) Cases of NRG1 Fusion in EU-5 (2019–2032)

Figure 22: Total Treated Cases of NRG1 Fusion in EU-5 (2019–2032)

Figure 23: Total Incident Cases of NRG1 Fusion in Japan (2019–2032)

Figure 24: Total Stage-specific Metastatic (including locally advanced) Cases of NRG1 Fusion in Japan (2019–2032)

Figure 25: Total Treated Cases of NRG1 Fusion in Japan (2019–2032)

Forward to Friend

Need A Quote